The Bioidentical Hormone Debate: Are Bioidentical Hormones (Estradiol, Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy?

References

• . The Endocrine Society. Bioidentical Hormones Position Statement, October 2006. http://www.endo-society.org/publicpolicy/policy/upload/BH_Position_Statement_final_10_25_06_w_Header.pdf. Accessed January 21, 2008.
   Google Scholar
• . Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381–387
   PubMedGoogle Scholar
• . Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9:253–263
   PubMed Web of Science ®Google Scholar
• . Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol. 2002;100(5 pt 1):853–863
   PubMed Web of Science ®Google Scholar
• . Greendale GA, Reboussin BA, Hogan P, . Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92(6):982–988
   PubMed Web of Science ®Google Scholar
• . Hargrove JT, Maxon WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone. Obstet Gynecol. 1989;73(4):606–612
   PubMed Web of Science ®Google Scholar
• . de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229–235
   PubMed Web of Science ®Google Scholar
• . Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95–108
   PubMed Web of Science ®Google Scholar
• . Ory K, Lebeau J, Levalois C, . Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat. 2001;68(3):187–198
   PubMed Web of Science ®Google Scholar
• . Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559–4565
   PubMed Web of Science ®Google Scholar
• . Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992;52(23):6539–6546
   PubMed Web of Science ®Google Scholar
• . Kalkhoven E, Kwakkenbos-Isbrücker L, de Laat SW, van der Saag PT, van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol. 1994;102(1–2):45–52
   PubMed Web of Science ®Google Scholar
• . Papa V, Reese CC, Brunetti A, Vigneri R, Siiteri PK, Goldfine ID. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. Cancer Res. 1990;50(24):7858–7862
   PubMed Web of Science ®Google Scholar
• . Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T-47D—possible therapeutic implications. Biochem Biophys Res Commun. 1987;145(2):706–711
   PubMed Web of Science ®Google Scholar
• . Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993;67(5):945–952
   PubMed Web of Science ®Google Scholar
• . Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125–134
   PubMed Web of Science ®Google Scholar
• . Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat. 1998;48(3):221–229
   PubMed Web of Science ®Google Scholar
• . Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 1996;174(1 pt 1):93–100
   PubMed Web of Science ®Google Scholar
• . Braunsberg H, Coldham NG, Wong W. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Lett. 1986;30(2):213–218
   PubMed Web of Science ®Google Scholar
• . van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42(5):457–465
   PubMed Web of Science ®Google Scholar
• . Saitoh M, Ohmichi M, Takahashi K, . Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005;146(11):4917–4925
   PubMed Web of Science ®Google Scholar
• . Chang KJ, Lee TY, Linares-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63(4):785–791
   PubMed Web of Science ®Google Scholar
• . Foidart JM, Colin C, Denoo X, . Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 1998;69(5):963–969
   PubMed Web of Science ®Google Scholar
• . Mueck AO, Seeger H, Wallwiener D. Comparison of proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric. 2003;6(3):221–227
   PubMed Web of Science ®Google Scholar
• . Inoh A, Kamiya K, Fujii Y, Yokoro K. Protective effects of progesterone and tamoxifen in estrogen induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn J Cancer Res. 1985;76(8):699–704
   PubMedGoogle Scholar
• . Barrat J, de Lignieres B, Marpeau L, . Effect in vivo de l'adminstration locale de progesterone sur l'activite mitotique des glaactorphores humains. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269–274
   PubMedGoogle Scholar
• . Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol. 2000;73(3–4):171–181
   PubMed Web of Science ®Google Scholar
• . Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179–188
   PubMed Web of Science ®Google Scholar
• . Soderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol. 1993;168(3 pt 1):874–879
   PubMed Web of Science ®Google Scholar
• . Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998;28(6):360–369
   PubMed Web of Science ®Google Scholar
• . Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7–v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem. 1999;202(1–2):53–61
   PubMed Web of Science ®Google Scholar
• . Groshong SD, Owen GI, Grimison B, . Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11(11):1593–1607
   PubMedGoogle Scholar
• . Segaloff A. Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat. Cancer Res. 1973;33(5):1136–1137
   PubMed Web of Science ®Google Scholar
• . Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998;158(3):401–407
   PubMed Web of Science ®Google Scholar
• . Jordan VC, Jeng MH, Catherino WH, Parker CJ. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 1993;71( 4 suppl):1501–1505
   PubMed Web of Science ®Google Scholar
• . Botella J, Duranti E, Viader V, Duc I, Delansorne R, Paris J. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosteorne derivatives on endometrial Ishikawa cells. J Steroid Biochem Mol Biol. 1995;55(1):77–84
   PubMed Web of Science ®Google Scholar
• . Botella J, Duc I, Delansorne R, Paris J, Lahlou B. Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989;248(2):758–761
   PubMed Web of Science ®Google Scholar
• . Markiewicz L, Hochberg RB, Gurpide E. Intrinsic estrogenicity of some progestogenic drugs. J Steroid Biochem Mol Biol. 1992;41(1):53–58
   PubMed Web of Science ®Google Scholar
• . Rabe T, Bohlmann MK, Rehberger-Schneider S, Prifti S. Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. Gynecol Endocrinol. 2000;14(2):118–126
   PubMed Web of Science ®Google Scholar
• . Campagnoli C, Abba C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005;97(5):441–450
   PubMed Web of Science ®Google Scholar
• . Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res. 2000;32(10):436–439
   PubMed Web of Science ®Google Scholar
• . Coldham NG, James VH. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int J Cancer. 1990;45(1):174–178
   PubMed Web of Science ®Google Scholar
• . Xu B, Kitawaki J, Koshiba H, . Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas. 2007;56(2):142–152
   PubMed Web of Science ®Google Scholar
• . Prost-Avallet O, Oursin J, Adessi GL. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. J Steroid Biochem Mol Biol. 1991;39(6):967–973
   PubMed Web of Science ®Google Scholar
• . Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003;46:45–54
   PubMed Web of Science ®Google Scholar
• . Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B. Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast. Mol Cell Endocrinol. 1977;6(4–5):333–348
   PubMed Web of Science ®Google Scholar
• . Fournier S, Kuttenn F, de Cicco F, Baudot N, Malet C, Mauvais-Jarvis P. Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endo Metab. 1982;55(3):428–433
   PubMed Web of Science ®Google Scholar
• . Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000;20(9):3102–3115
   PubMed Web of Science ®Google Scholar
• . Wei LL, Gonzalez-Aller C, Wood WM, Miller LA, Horwitz KB. 5′-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated “C”-receptor and unique A-receptor messages. Mol Endocrinol. 1990;4(12):1833–1840
   PubMedGoogle Scholar
• . Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163–172
   PubMed Web of Science ®Google Scholar
• . Graham JD, Clarke C. Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res. 2002;4(5):187–190
   PubMed Web of Science ®Google Scholar
• . Kastner P, Krust A, Turcotte B, . Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9(5):1603–1614
   PubMed Web of Science ®Google Scholar
• . Mote P, Clarke C. Relative expression of progesterone receptors A and B in premalignant and invasive breast lesions. Breast Cancer Res. 2000;2( suppl 1):P2.01
   Google Scholar
• . Hopp TA, Weiss HL, Hilsenbeck SG, . Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10(8):2751–2760
   PubMed Web of Science ®Google Scholar
• . Isaksson E, Wang H, Sahlin L, von Schoultz B, Cline JM, von Schoultz E. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue form surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat. 2003;79(2):233–239
   PubMed Web of Science ®Google Scholar
• . Vereide AB, Kaino T, Sager G, Arnes M, Ørbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101(2):214–223
   PubMed Web of Science ®Google Scholar
• . Custodia-Lora N, Novillo A, Callard IP. Regulation of hepatic progesterone and estrogen receptors in the female turtle, Chrysemys picta: relationship to vitellogenesis. Gen Comp Endocrinol. 2004;136(2):232–240
   PubMed Web of Science ®Google Scholar
• . Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454
   PubMed Web of Science ®Google Scholar
• . Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111
   PubMed Web of Science ®Google Scholar
• . Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(4):361–368
   PubMed Web of Science ®Google Scholar
• . Micheli A, Muti P, Secreto G, . Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112(2):312–318
   PubMed Web of Science ®Google Scholar
• . Gottardis M, Ertürk E, Rose DP. Effects of progesterone administration on N-nitrosomethylurea-induced rat mammary carcinogenesis. Eur J Cancer Clin Oncol. 1983;19(10):1479–1484
   PubMedGoogle Scholar
• . Grubbs CJ, Farnell DR, Hill DL, McDonough KC. Chemoprevention of N-nitroso-N-methylurea induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. J Natl Cancer Inst. 1985;74(4):927–931
   PubMedGoogle Scholar
• . Kledzik GS, Bradley CJ, Meites J. Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res, 1974;34(11):2953–2956
   PubMed Web of Science ®Google Scholar
• . Welsch CH, Clemens JA, Meites J. Effects of multiple pituitary homografts or progesterone on 7, 12-dimethylbenz[a]anthracene-induced mammary tumors in rats. J Natl Cancer Inst. 1968;41(2):465–478
   PubMedGoogle Scholar
• . Bernstein L, Yuan JM, Ross RK, . Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control. 1990;1(1):51–58
   PubMed Web of Science ®Google Scholar
• . Drafta D, Schindler AE, Milcu SM, . Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem. 1980;13(7):793–802
   PubMedGoogle Scholar
• . Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977;37(12):4655–4659
   PubMed Web of Science ®Google Scholar
• . Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst. 1986;77(3):613–616
   PubMedGoogle Scholar
• . Secreto G, Toniolo P, Berrino F, . Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 1984(12 pt 1); 44:5902–5905
   Google Scholar
• . Rossouw JE, Anderson GL, Prentice RL, ; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333
   PubMed Web of Science ®Google Scholar
• . Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712
   PubMed Web of Science ®Google Scholar
• . Chlebowski RT, Hendrix SL, Langer RD, . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253
   PubMed Web of Science ®Google Scholar
• . Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control. 2002;13(9):847–854
   PubMed Web of Science ®Google Scholar
• . Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049–2058
   PubMed Web of Science ®Google Scholar
• . Ewertz M, Mellemkjaer L, Poulsen AH, . Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92(7):1293–1297
   PubMed Web of Science ®Google Scholar
• . Newcomb PA, Titus-Ernstoff L, Egan KM, . Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epid Bio Prev. 2002;11(7):593–600
   PubMed Web of Science ®Google Scholar
• . Stahlberg C, Pedersen AT, Lynge E, . Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109(5):721–727
   PubMed Web of Science ®Google Scholar
• . Li CI. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas. 2004;49(1):44–50
   PubMed Web of Science ®Google Scholar
• . Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999;81(3):339–344
   PubMed Web of Science ®Google Scholar
• . Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA. 2000;284(6):691–694
   PubMedGoogle Scholar
• . Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–332
   PubMed Web of Science ®Google Scholar
• . Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190(4):1141–1167
   PubMed Web of Science ®Google Scholar
• . Weiss LK, Burkman RT, Cushing-Haugen KL, . Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol. 2002;100(6):1148–1158
   PubMed Web of Science ®Google Scholar
• . Li CI, Malone KE, Porter PL, . Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–3263
   PubMed Web of Science ®Google Scholar
• . Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427
   PubMed Web of Science ®Google Scholar
• . Kirsh V, Kreiger N. Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13(6):583–590
   PubMed Web of Science ®Google Scholar
• . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047–1059
   PubMed Web of Science ®Google Scholar
• . Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485–491
   PubMed Web of Science ®Google Scholar
• . Colditz G, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol. 1998;147:S45
   Web of Science ®Google Scholar
• . Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10(4):253–260
   PubMed Web of Science ®Google Scholar
• . Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–741
   PubMed Web of Science ®Google Scholar
• . Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000;65(10–11):659–664
   PubMed Web of Science ®Google Scholar
• . Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 2001;86(1):16–23
   PubMed Web of Science ®Google Scholar
• . Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand. 2003;82(7):335–344
   Web of Science ®Google Scholar
• . Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003;97(6):1387–1392
   PubMed Web of Science ®Google Scholar
• . Colditz GA, Hankinson SE, Hunter DJ, . The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589–1593
   PubMed Web of Science ®Google Scholar
• . Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152(10):950–964
   PubMed Web of Science ®Google Scholar
• . Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114(2):209–217
   PubMed Web of Science ®Google Scholar
• . Badwe RA, Wang DY, Gregory WM, . Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994;30A(4):445–448
   PubMed Web of Science ®Google Scholar
• . Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996;73(12):1552–1555
   PubMed Web of Science ®Google Scholar
• . Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol. 1991;95(1):30–34
   PubMed Web of Science ®Google Scholar
• . Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306–311
   PubMed Web of Science ®Google Scholar
• . Troisi R, Weiss HA, Hoover RN, . Pregnancy characteristics and maternal risk of breast cancer. Epidemiology. 1998;9(6):641–647
   PubMed Web of Science ®Google Scholar
• . Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer. 2002;87(9):971–973
   PubMed Web of Science ®Google Scholar
• . Paruthiyil S, Parma H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest. Cancer Res. 2004;64(1):423–428
   PubMed Web of Science ®Google Scholar
• . Paech K, Webb P, Kuiper GG, . Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties. Science. 1997;277(5331):1508–1510
   PubMed Web of Science ®Google Scholar
• . Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93(12):5925–5930
   PubMed Web of Science ®Google Scholar
• . Green S, Walter P, Greene G, . Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986;24(1):77–83
   PubMedGoogle Scholar
• . Katzenellenbogen BS, Montano MM, Ediger TR, . Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163–193
   PubMedGoogle Scholar
• . Nilsson S, Mäkelä S, Treuter E, . Mechanisms of estrogen action. Physiol Rev. 2001;81(4):1535–1565
   PubMed Web of Science ®Google Scholar
• . Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44):6605–6616
   PubMed Web of Science ®Google Scholar
• . Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–551
   PubMed Web of Science ®Google Scholar
• . Isaksson E, Wang H, Sahlin L, . Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-1 in breast tissue form surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast. 2002;11(4):295–300
   PubMed Web of Science ®Google Scholar
• . Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol. 2001;8(5):427–436
   PubMedGoogle Scholar
• . Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts a dominant regulator of estrogen signaling. Oncogene. 2000;19(43):4970–4978
   PubMed Web of Science ®Google Scholar
• . Saji S, Jensen EV, Nilsson S, Rylander T, Warner, Gustafsson JA. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A. 2000;97(1):337–342
   PubMed Web of Science ®Google Scholar
• . Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147(9):4132–4150
   PubMed Web of Science ®Google Scholar
• . Rich RL, Hoth LR, Geoghegan KF, . Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci U S A. 2002;99(13):8562–8567
   PubMed Web of Science ®Google Scholar
• . Ekena K, Katzenellenbogen JA, Katzenellenbogen BS. Determinants of ligand specificity of estrogen receptor-alpha: estrogen versus androgen discrimination. J Biol Chem. 1998;273(2):693–699
   PubMed Web of Science ®Google Scholar
• . Hanstein B, Liu H, Yancisin MC, Brown M. Functional analysis of a novel estrogen receptor-beta isoform. Mol Endocrinol. 1999;13(1):129–137
   PubMedGoogle Scholar
• . Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17–27
   PubMedGoogle Scholar
• . Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer. 1989;63(9):1685–1692
   PubMed Web of Science ®Google Scholar
• . Lemon HM. Estriol prevention of mammary carcinoma induced by 7, 12-dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35(5):1341–1353
   PubMed Web of Science ®Google Scholar
• . MacMahon B, Cole P, Brown JB, . Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900–902
   PubMed Web of Science ®Google Scholar
• . Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54(1):105–112
   PubMed Web of Science ®Google Scholar
• . Pisha E, Lui X, Constantinou AI, Bolton JL. Evidence that a metabolite of equine estrogens, 4-hydroxequilenin, induces cellular transformation in vitro. Chem Res Toxicol. 2001;14(1):82–90
   PubMed Web of Science ®Google Scholar
• . Zhang F, Chen Y, Pisha E, . The major metabolite of equilin, 4-hyroxyequilin, autoxidizes to an o-quinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone. Chem Res Toxicol. 1999;12(2):204–213
   PubMed Web of Science ®Google Scholar
• . Chen Y, Liu X, Pisha E, . A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol. 2000;13(5):342–350
   PubMed Web of Science ®Google Scholar
• . Zhang F, Swanson SM, van Breemen RB, . Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol. 2001;14(12):1654–1659
   PubMed Web of Science ®Google Scholar
• . Shen L, Qiu S, Chen Y, . Alkylation of 2′-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical. Chem Res Toxicol. 1998;11(2):94–101
   PubMed Web of Science ®Google Scholar
• . Gross J, Modan B, Bertini B, . Relationship between steroid excretion patterns and breast cancer incidence in Israeli women of various origins. J Natl Cancer Inst. 1997;59(1):7–11
   Google Scholar
• . Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1(7595):604–606
   PubMed Web of Science ®Google Scholar
• . Dickinson LE, MacMahon B, Cole P, Brown JB. Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med. 1974;291(23):1211–1213
   PubMed Web of Science ®Google Scholar
• . Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868–1878
   PubMedGoogle Scholar
• . Speroff L. The breast as an endocrine target organ. Contemp Obstet Gynec. 1977;9:69–72
   Google Scholar
• . Rosner B, Colditz, GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994;139(8):819–835
   PubMed Web of Science ®Google Scholar
• . Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;2(1):5–73
   PubMedGoogle Scholar
• . Pasqualini JR. The fetus, pregnancy, and breast cancer. In: Pasqualini JR, ed. Breast Cancer: Prognosis, Treatment, and Prevention. New York, NY: Marcel Dekker Inc; 2002:19–71
   Google Scholar
• . Vatten LJ, Romundstad PR, Trichopoulos D, Skjaærven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;87(3):289–290
   PubMed Web of Science ®Google Scholar
• . Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D. Intrauterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst. 1997;89(1):71–76
   PubMedGoogle Scholar
• . Ursin G, Wilson M, Henderson BE, . Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61(8):3326–3329
   PubMed Web of Science ®Google Scholar
• . Lemon HM. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. J Surg Oncol. 1972;4(3):255–273
   PubMedGoogle Scholar
• . Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004;112(1):130–134
   PubMed Web of Science ®Google Scholar
• . Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977;37(6):1901–1907
   PubMed Web of Science ®Google Scholar
• . Lemon HM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196(13):1128–136
   PubMed Web of Science ®Google Scholar
• . Marmorston J, Fowley LG, Myers SM, Stern E, Hopkins CE. II. Urinary excretion of estrone, estradiol and estriol by patients with breast cancer and benign breast disease. Am J Obstet Gynecol. 1965;92:460–467
   PubMed Web of Science ®Google Scholar
• . Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol. 1985;151(6):746–750
   PubMed Web of Science ®Google Scholar
• . Minshall RD, Stanczyk FZ, Miyagawa K, . Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649–659
   PubMed Web of Science ®Google Scholar
• . Mishra RG, Hermsmeyer RK, Miyagawas K, . Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. J Clin Endocrinol Metab. 2005;90(6):3706–3714
   PubMed Web of Science ®Google Scholar
• . Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324–327
   PubMed Web of Science ®Google Scholar
• . Adams MR, Register TC, Golden DL, Wagner JD, Williams J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217–221
   PubMed Web of Science ®Google Scholar
• . Saarikoski S, Yliskoski M, Penttilä I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas. 1990;12(2):89–97
   PubMed Web of Science ®Google Scholar
• . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208
   PubMed Web of Science ®Google Scholar
• . Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447–453
   PubMed Web of Science ®Google Scholar
• . Larsson-Cohn U, Fåhraeus L, Wallentin L, Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril. 1981;35(2):172–179
   PubMed Web of Science ®Google Scholar
• . Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37
   PubMedGoogle Scholar
• . Mälkönen M, Manninen V, Hirvonen E. Effects of danazol and lynestrenol on serum lipoproteins in endometriosis. Clin Pharmacol Ther. 1980;28(5):602–604
   PubMed Web of Science ®Google Scholar
• . Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 1981;304(10):560–563
   PubMed Web of Science ®Google Scholar
• . Cushman M, Kuller LH, Prentice R, . Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580
   PubMed Web of Science ®Google Scholar
• . Canonico M, Oger E, Plu-Bureau G, . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845
   PubMed Web of Science ®Google Scholar
• . Rosano GM, Webb CM, Chierchia S, . Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154–2159
   PubMed Web of Science ®Google Scholar
• . Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol. 1991;77(2):235–240
   PubMed Web of Science ®Google Scholar
• . Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94(9):2221–2227
   PubMed Web of Science ®Google Scholar
• . Otsuki M, Saito H, Xu X, . Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21(2):243–248
   PubMed Web of Science ®Google Scholar
• . Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998;18(7):1164–1171
   PubMed Web of Science ®Google Scholar
• . Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism. 1996;45(10):1254–1262
   PubMed Web of Science ®Google Scholar
• . Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60(4):664–667
   PubMed Web of Science ®Google Scholar
• . Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism. 2000;49(6):742–747
   PubMed Web of Science ®Google Scholar
• . Godsland IF, Gangar K, Walton C, . Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 1993;42(7):846–853
   PubMed Web of Science ®Google Scholar
• . Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle-aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64
   PubMedGoogle Scholar
• . Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause. 2006;13(1):80–86
   PubMed Web of Science ®Google Scholar
• . Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1):66–71
   PubMed Web of Science ®Google Scholar
• . Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement on therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24(7):1757–1761
   PubMed Web of Science ®Google Scholar
• . Adams MR, Kaplan JR, Manuck SB, . Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10(6):1051–1057
   PubMedGoogle Scholar
• . Bolaji II, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O'Dwyer EM. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61–68
   PubMed Web of Science ®Google Scholar
• . Morey AK, Pedram A, Razandi M, . Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138(8):3330–3339
   PubMed Web of Science ®Google Scholar
• . Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997;3(9):1005–1008
   PubMed Web of Science ®Google Scholar
• . Minshall RD, Miyagawa K, Chadwick CC, Novy MJ, Hermsmeyer K. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. FASEB J. 1998;12(13):1419–1429
   PubMed Web of Science ®Google Scholar
• . Minshall RD, Pavcnik D, Halushka PV, Hermsmeyer RK. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol. 2001;281(4):H1498–H1507
   Web of Science ®Google Scholar
• . Houser SL, Aretz HT, Quist WC, Chang Y, Schreiber AD. Serum lipids and arterial plaque load are altered independently with high-dose progesterone in hypercholesterolemic male rabbits. Cardiovasc Pathol. 2000;9(6):317–322
   PubMed Web of Science ®Google Scholar
• . Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071–3078
   PubMed Web of Science ®Google Scholar
• . Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas. 2005;50(1):39–43
   PubMed Web of Science ®Google Scholar
• . Oger E, Alhenc-Gelas M, Lacut K, . Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671–1676
   PubMed Web of Science ®Google Scholar
• . Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339–346
   PubMed Web of Science ®Google Scholar
• . Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives contain norgestimate and 35 μg of ethinyl estradiol. Contraception. 2006;73(3):223–228
   PubMed Web of Science ®Google Scholar
• . Hellman I, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42(5):912–917
   PubMed Web of Science ®Google Scholar
• . Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S. Clinical trial of high-dose oral medroxyprogesteorne acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988;61(11):2161–2167
   PubMed Web of Science ®Google Scholar
• . Corvol P, Elkik F, Feneant M, . Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and Progestins. New York, NY: Raven Press; 1983;1979–1986
   Google Scholar
• . Rylance PB, Brincat M, Lafferty K, . Natural progesterone and antihypertensive action. Bri Med J. 1985(6461);290:13–14
   PubMedGoogle Scholar
• . Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab. 1993;76(2):472–475
   PubMed Web of Science ®Google Scholar
• . Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. JAMA. 1978;239(16):1638–1641
   PubMed Web of Science ®Google Scholar
• . Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei). 1995;55:386–391
   Google Scholar
• . Perović D, Kopajtic B, Stanković T. Treatment of climacteric complaints with oestriol. Arzneimittel-Forschung. 1975;25(6):962–964
   PubMed Web of Science ®Google Scholar
• . van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol. 1993;51(1):29–33
   PubMed Web of Science ®Google Scholar
• . Cardoza L, Rekers H, Tapp A, . Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47–53
   PubMedGoogle Scholar